✦ LIBER ✦

Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion

✍ Scribed by Werner B.F. Brouwer; Marc A. Koopmanschap; Frans F.H. Rutten

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 25 KB
Volume: 6
Category: Article
ISSN: 1057-9230
DOI: 10.1002/(sici)1099-1050(199709)6:5<511::aid-hec297>3.0.co;2-k

No coin nor oath required. For personal study only.

✦ Synopsis

In this response we concentrate on what Weinstein et al. call the 'major disagreement' between the Erasmus group and the US Panel, which concerns the measurement of productivity losses during illness. We consider the consequences for the individual, for the employer and for the rest of society and argue that when following the Panel's propositions for measuring these consequences, major theoretical and practical difficulties are encountered.

📜 SIMILAR VOLUMES

Posaconazole versus fluconazole or itrac

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

✍ George Dranitsaris; Haytham Khoury 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 217 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB